Akari Therapeutics (ADR) (AKTX)
Develops preclinical oncology antibody-drug conjugates based on its PH1 payload platform.
Something off on this page? Send us feedback.
Develops a preclinical oncology ADC platform and anti-cancer candidates using novel payloads; AKTX-101 pairs a TROP2 target with PH1. The development-stage business focuses on research, development, and capital raising.
Following the Peak Bio acquisition, substantially all work has centered on a preclinical oncology antibody-drug-conjugate platform and anti-cancer candidates with novel payloads applied to clinically validated targets. AKTX-101, the lead program, pairs a TROP2 target with its PH1 payload.
The present legal entity was established in England in 2004 and maintains its principal US office in Tampa, Florida; its ADSs trade on Nasdaq. The development-stage business has conducted research, development, and capital-raising activities since inception.
Development of the platform and pipeline depends on additional capital. The current operating frame was shaped by the Peak Bio transaction.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Jul 20, 2026 | Maxim Group | Upgrade | Hold | Buy | $30 |
| Apr 8, 2026 | Maxim Group | Downgrade | Buy | Hold |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.7M · Total debt $693.0K · Total assets $38.6M · Shareholders' equity $18.6M
- Revenue
- $0
- Operating income
- −$4.6M
- Net income
- −$4.8M
No dividends on record.
| Institutions6 holders · as of Mar 31, 2026 | 5.83% | 66.7K ADS | |
| Insiders2 holders · as of Aug 19, 2026 | 2.13% | 24.4K ADS | |
| Otherremainder | 92.04% | 1.05M ADS |
1.14M ADS as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Armistice Capital, LLCInstitution | 3.40% | 38,922 ADS | 13Fas of Mar 31, 2026 |
Kameel D. FaragInsiderofficer: Interim CFO | 2.04% | 23,309 ADS | Form 4filed Aug 19, 2026 ↗ |
Cresset Asset Management, LLCInstitution | 1.80% | 20,561 ADS | 13Fas of Mar 31, 2026 |
Ifp Advisors, IncInstitution | 0.63% | 7,250 ADS | 13Fas of Mar 31, 2026 |
Robert B. BazemoreInsiderdirector | 0.10% | 1,116 ADS | Form 4filed Mar 10, 2025 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 16, 2025 | James R. Neal | director | +11,132 | $0.3883 |
| Dec 16, 2025 | Robert B. Bazemore | director | +309,326 | $0.3883 |
| Dec 16, 2025 | Abizer Gaslightwala | director, officer: CEO | +2,165,302 | $0.3883 |
| Dec 16, 2025 | Samir Rashmikant Patel | director, 10 percent owner: | +1,701,310 | $0.3883 |
| Dec 16, 2025 | Kameel D. Farag | officer: Interim CFO | +49,490 | $0.3883 |
- Gilead Sciences
Approved TROP2 ADC for breast cancer with an SN-38 payload
- Merck
Global Phase 3 TROP2 ADC development with sacituzumab tirumotecan
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Akari Therapeutics (ADR) | $10.02 | −1.28% | $11.6M | — | — | — | — |
| Gilead Sciences | $149.25 | −0.24% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| Merck | $151.87 | +0.15% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Median | 121.3 | 17.0 | 5.9 | +7.6% |